Orodispersible Tablet Formulation Containing Montelukast
Publication Date: 2007-Apr-30
The IP.com Prior Art Database
Montelukast, a leukotriene D4 antagonist for the treatment of chronic asthma and allergic rhinitis is marketed under the tradename SINGULAIR® in orodispersible tablet formulations of 4 mg and 5 mg, and in a film-coated tablet formulation of 10 mg. The orodispersible tablet formulations contain aspartame as sweetener, which provides an adequate taste-masking of the bitter tasting active pharmaceutical ingredient. We developed a formulation without aspartame.